1. Home
  2. EQH vs BIIB Comparison

EQH vs BIIB Comparison

Compare EQH & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equitable Holdings Inc.

EQH

Equitable Holdings Inc.

HOLD

Current Price

$46.01

Market Cap

16.2B

Sector

Finance

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.61

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQH
BIIB
Founded
1859
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.2B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
EQH
BIIB
Price
$46.01
$181.61
Analyst Decision
Buy
Buy
Analyst Count
11
23
Target Price
$64.18
$176.48
AVG Volume (30 Days)
2.9M
1.9M
Earning Date
11-04-2025
10-30-2025
Dividend Yield
2.36%
N/A
EPS Growth
N/A
N/A
EPS
N/A
10.97
Revenue
$12,224,000,000.00
$10,065,900,000.00
Revenue This Year
$25.11
$3.61
Revenue Next Year
$5.01
N/A
P/E Ratio
N/A
$16.52
Revenue Growth
13.38
4.77
52 Week Low
$41.39
$110.04
52 Week High
$56.61
$185.17

Technical Indicators

Market Signals
Indicator
EQH
BIIB
Relative Strength Index (RSI) 48.39 72.92
Support Level $44.30 $174.53
Resistance Level $46.17 $182.94
Average True Range (ATR) 1.25 5.22
MACD 0.27 0.25
Stochastic Oscillator 71.73 83.54

Price Performance

Historical Comparison
EQH
BIIB

About EQH Equitable Holdings Inc.

Equitable Holdings Inc is a financial services company in the U.S. The company provides variable annuities, tax-deferred investment and retirement plans, employee benefits, and protection solutions for individuals, families, and small businesses. Its business segments include Individual Retirement, Group Retirement, Asset Management, Protection Solutions, Wealth Management, and Legacy. It generates the majority of its revenue from the Asset Management segment which provides diversified investment management and related solutions globally to a broad range of clients through three main client channels - Institutional, Retail, and Private Wealth.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: